With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.173035-10-4,1,3-Dimesityl-4,5-dihydro-1H-imidazol-3-ium chloride,as a common compound, the synthetic route is as follows.
Synthesis of [(SIMes)CuCl]. This synthesis is as reported in the literature; see S. Diez-Gonzalez et al., J. Org. Chem. 2005, 70, 4784-4796. In a 250 mL Schlenk flask were added copper(I) chloride (1.0 g, 10.10 mmol), 1,3-bis(2,4,6-trimethylphenyl)-4,5-dihydro-imidazol-2-ylidenium chloride (SIMes-HCl, 10.10 mmol), and sodium tert-butoxide (0.97 g, 10.10 mmol). To this flask, dry tetrahydrofuran (100 mL) was added under an inert atmosphere of argon, and the mixture was magnetically stirred for 20 hours at room temperature. After the mixture was filtered through a plug of Celite and then evaporating the solvent under vacuum, a white solid was obtained. 1H NMR (400 MHz, CDCl3) delta=6.96 (s, 4H), 3.96 (s, 4H), 2.32 (s, 12H), 2.30 (s, 6H); 13C NMR (100 MHz, CDCl3) delta=202.8, 138.7, 135.3, 135.0, 129.7, 50.9, 21.0, 18.0. Elemental analysis calcd for C21H26CuClN2: C, 62.21; H, 6.46; N, 6.91. Found: C, 62.60; H, 6.52; N, 6.80%., 173035-10-4
As the paragraph descriping shows that 173035-10-4 is playing an increasingly important role.
Reference£º
Patent; Institut Catala d’Investigacio Quimica; Institucio Catalana de Recerca i Estudis Avancats; US2009/69569; (2009); A1;,
Chiral Catalysts
Chiral catalysts – SlideShare